Arrowstreet Capital’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.26M | Buy |
+336,438
| New | +$7.26M | 0.01% | 1012 |
|
|
2023
Q4 | – | Sell |
-54,901
| Closed | -$1.14M | – | 1383 |
|
|
2023
Q3 | $1.14M | Buy |
+54,901
| New | +$1.14M | ﹤0.01% | 955 |
|
|
2022
Q3 | – | Sell |
-61,099
| Closed | -$861K | – | 1246 |
|
|
2022
Q2 | $861K | Buy |
+61,099
| New | +$861K | ﹤0.01% | 966 |
|
|
2021
Q1 | – | Sell |
-6,100
| Closed | -$326K | – | 2203 |
|
|
2020
Q4 | $326K | Sell |
6,100
-137,661
| -96% | -$7.36M | ﹤0.01% | 2103 |
|
|
2020
Q3 | $5.93M | Sell |
143,761
-142,373
| -50% | -$5.87M | 0.01% | 1080 |
|
|
2020
Q2 | $13.9M | Buy |
286,134
+253,134
| +767% | +$12.3M | 0.03% | 647 |
|
|
2020
Q1 | $1.39M | Sell |
33,000
-614,248
| -95% | -$25.9M | ﹤0.01% | 1195 |
|
|
2019
Q4 | $27.7M | Buy |
+647,248
| New | +$27.7M | 0.06% | 309 |
|